362 related articles for article (PubMed ID: 28062799)
1. A Two-pronged Binding Mechanism of IgG to the Neonatal Fc Receptor Controls Complex Stability and IgG Serum Half-life.
Jensen PF; Schoch A; Larraillet V; Hilger M; Schlothauer T; Emrich T; Rand KD
Mol Cell Proteomics; 2017 Mar; 16(3):451-456. PubMed ID: 28062799
[TBL] [Abstract][Full Text] [Related]
2. Investigating the interaction between the neonatal Fc receptor and monoclonal antibody variants by hydrogen/deuterium exchange mass spectrometry.
Jensen PF; Larraillet V; Schlothauer T; Kettenberger H; Hilger M; Rand KD
Mol Cell Proteomics; 2015 Jan; 14(1):148-61. PubMed ID: 25378534
[TBL] [Abstract][Full Text] [Related]
3. A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life.
Souders CA; Nelson SC; Wang Y; Crowley AR; Klempner MS; Thomas W
MAbs; 2015; 7(5):912-21. PubMed ID: 26018774
[TBL] [Abstract][Full Text] [Related]
4. Conformational Destabilization of Immunoglobulin G Increases the Low pH Binding Affinity with the Neonatal Fc Receptor.
Walters BT; Jensen PF; Larraillet V; Lin K; Patapoff T; Schlothauer T; Rand KD; Zhang J
J Biol Chem; 2016 Jan; 291(4):1817-1825. PubMed ID: 26627822
[TBL] [Abstract][Full Text] [Related]
5. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR.
Suzuki T; Ishii-Watabe A; Tada M; Kobayashi T; Kanayasu-Toyoda T; Kawanishi T; Yamaguchi T
J Immunol; 2010 Feb; 184(4):1968-76. PubMed ID: 20083659
[TBL] [Abstract][Full Text] [Related]
6. Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics.
Schoch A; Kettenberger H; Mundigl O; Winter G; Engert J; Heinrich J; Emrich T
Proc Natl Acad Sci U S A; 2015 May; 112(19):5997-6002. PubMed ID: 25918417
[TBL] [Abstract][Full Text] [Related]
7. Are endosomal trafficking parameters better targets for improving mAb pharmacokinetics than FcRn binding affinity?
Gurbaxani B; Dostalek M; Gardner I
Mol Immunol; 2013 Dec; 56(4):660-74. PubMed ID: 23917469
[TBL] [Abstract][Full Text] [Related]
8. V Region of IgG Controls the Molecular Properties of the Binding Site for Neonatal Fc Receptor.
Rossini S; Noé R; Daventure V; Lecerf M; Justesen S; Dimitrov JD
J Immunol; 2020 Nov; 205(10):2850-2860. PubMed ID: 33077645
[TBL] [Abstract][Full Text] [Related]
9. Insight into the avidity-affinity relationship of the bivalent, pH-dependent interaction between IgG and FcRn.
Reusch J; Andersen JT; Rant U; Schlothauer T
MAbs; 2024; 16(1):2361585. PubMed ID: 38849969
[TBL] [Abstract][Full Text] [Related]
10. Combined glyco- and protein-Fc engineering simultaneously enhance cytotoxicity and half-life of a therapeutic antibody.
Monnet C; Jorieux S; Souyris N; Zaki O; Jacquet A; Fournier N; Crozet F; de Romeuf C; Bouayadi K; Urbain R; Behrens CK; Mondon P; Fontayne A
MAbs; 2014; 6(2):422-36. PubMed ID: 24492301
[TBL] [Abstract][Full Text] [Related]
11. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn).
Dall'Acqua WF; Kiener PA; Wu H
J Biol Chem; 2006 Aug; 281(33):23514-24. PubMed ID: 16793771
[TBL] [Abstract][Full Text] [Related]
12. Cross-species analysis of Fc engineered anti-Lewis-Y human IgG1 variants in human neonatal receptor transgenic mice reveal importance of S254 and Y436 in binding human neonatal Fc receptor.
Burvenich IJ; Farrugia W; Lee FT; Catimel B; Liu Z; Makris D; Cao D; O'Keefe GJ; Brechbiel MW; King D; Spirkoska V; Allan LC; Ramsland PA; Scott AM
MAbs; 2016; 8(4):775-86. PubMed ID: 27030023
[TBL] [Abstract][Full Text] [Related]
13. Qualification of a homogeneous cell-based neonatal Fc receptor (FcRn) binding assay and its application to studies on Fc functionality of IgG-based therapeutics.
Mathur A; Arora T; Liu L; Crouse-Zeineddini J; Mukku V
J Immunol Methods; 2013 Apr; 390(1-2):81-91. PubMed ID: 23384837
[TBL] [Abstract][Full Text] [Related]
14. Characterization of the interactions of rabbit neonatal Fc receptor (FcRn) with rabbit and human IgG isotypes.
Szikora B; Hiripi L; Bender B; Kacskovics I; Iliás A
PLoS One; 2017; 12(9):e0185662. PubMed ID: 28957416
[TBL] [Abstract][Full Text] [Related]
15. Monoclonal antibodies with identical Fc sequences can bind to FcRn differentially with pharmacokinetic consequences.
Wang W; Lu P; Fang Y; Hamuro L; Pittman T; Carr B; Hochman J; Prueksaritanont T
Drug Metab Dispos; 2011 Sep; 39(9):1469-77. PubMed ID: 21610128
[TBL] [Abstract][Full Text] [Related]
16. Impact of methionine oxidation in human IgG1 Fc on serum half-life of monoclonal antibodies.
Wang W; Vlasak J; Li Y; Pristatsky P; Fang Y; Pittman T; Roman J; Wang Y; Prueksaritanont T; Ionescu R
Mol Immunol; 2011 Mar; 48(6-7):860-6. PubMed ID: 21256596
[TBL] [Abstract][Full Text] [Related]
17. Humanized FcRn mouse models for evaluating pharmacokinetics of human IgG antibodies.
Proetzel G; Roopenian DC
Methods; 2014 Jan; 65(1):148-53. PubMed ID: 23867339
[TBL] [Abstract][Full Text] [Related]
18. Antigen physiochemical properties allosterically effect the IgG Fc-region and Fc neonatal receptor affinity.
Sun Y; Estevez A; Schlothauer T; Wecksler AT
MAbs; 2020; 12(1):1802135. PubMed ID: 32795110
[TBL] [Abstract][Full Text] [Related]
19. Neonatal Fc receptor (FcRn): a novel target for therapeutic antibodies and antibody engineering.
Wang Y; Tian Z; Thirumalai D; Zhang X
J Drug Target; 2014 May; 22(4):269-78. PubMed ID: 24404896
[TBL] [Abstract][Full Text] [Related]
20. Changes in complementarity-determining regions significantly alter IgG binding to the neonatal Fc receptor (FcRn) and pharmacokinetics.
Piche-Nicholas NM; Avery LB; King AC; Kavosi M; Wang M; O'Hara DM; Tchistiakova L; Katragadda M
MAbs; 2018 Jan; 10(1):81-94. PubMed ID: 28991504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]